← FDA DRUG APPROVALS

FDA ANDA · ANDA200624

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

Sponsor: LUPIN

APPLICATION
ANDA200624
TYPE
ANDA
ORIGINAL APPROVAL
2015-07-15
LATEST ACTION
2015-07-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

REPAGLINIDE AND METFORMIN HYDROCHLORIDEDiscontinued
METFORMIN HYDROCHLORIDE 500MG, REPAGLINIDE 1MG · TABLET · ORAL
REPAGLINIDE AND METFORMIN HYDROCHLORIDEDiscontinued
METFORMIN HYDROCHLORIDE 500MG, REPAGLINIDE 2MG · TABLET · ORAL

Approval history

2015-07-15Not Applicable · Original — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →